Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

Apr 19, 2024

BUY
$108.01 - $179.35 $43,204 - $71,740
400 New
400 $6,000
Q4 2021

Jan 18, 2022

BUY
$39.81 - $88.24 $1.1 Million - $2.44 Million
27,700 Added 96.18%
56,500 $236,000
Q3 2021

Oct 26, 2021

BUY
$52.01 - $71.77 $1.5 Million - $2.07 Million
28,800 New
28,800 $486,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.02B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.